AIM ImmunoTech (AIM) stock price, revenue, and financials

AIM ImmunoTech market cap is $84.2 m, and annual revenue was $140 k in FY 2019

$84.2 M

AIM Mkt cap, 11-Jan-2021

$40 K

AIM ImmunoTech Revenue Q2, 2020
AIM ImmunoTech Gross profit (Q2, 2020)-160 K
AIM ImmunoTech Gross profit margin (Q2, 2020), %(400%)
AIM ImmunoTech Net income (Q2, 2020)-3.4 M
AIM ImmunoTech EBIT (Q2, 2020)-3.3 M
AIM ImmunoTech Cash, 30-Jun-202033.9 M
AIM ImmunoTech EV52.8 M

AIM ImmunoTech Revenue

AIM ImmunoTech revenue was $140 k in FY, 2019

Embed Graph

AIM ImmunoTech Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

36.0k45.0k72.0k49.0k39.0k42.0k36.0k36.0k76.0k36.0k45.0k36.0k47.0k23.0k39.0k15.0k22.0k84.0k213.0k90.0k56.0k33.0k38.0k29.0k61.0k45.0k40.0k

Cost of goods sold

204.0k217.0k280.0k208.0k988.0k191.0k635.0k252.0k323.0k294.0k306.0k372.0k507.0k353.0k268.0k290.0k272.0k270.0k218.0k399.0k208.0k186.0k208.0k231.0k215.0k230.0k204.0k200.0k

Gross profit

(168.0k)(172.0k)(208.0k)(159.0k)(949.0k)(149.0k)(599.0k)(216.0k)(247.0k)(258.0k)(261.0k)(336.0k)(460.0k)(330.0k)(229.0k)(275.0k)(250.0k)(186.0k)(5.0k)(309.0k)(152.0k)(153.0k)(170.0k)(186.0k)(169.0k)(159.0k)(160.0k)

Gross profit Margin, %

(467%)(382%)(289%)(324%)(2433%)(355%)(1664%)(600%)(325%)(717%)(580%)(933%)(979%)(1435%)(587%)(1833%)(1136%)(221%)(2%)(343%)(271%)(464%)(447%)(641%)(277%)(353%)(400%)

R&D expense

1.6m1.8m1.7m1.7m2.4m2.3m2.3m2.2m2.3m2.3m1.9m2.7m2.4m2.0m1.0m900.0k1.3m1.4m1.1m787.0k855.0k1.3m1.6m928.0k1.1m1.2m898.0k1.5m

General and administrative expense

1.5m1.6m1.9m1.7m1.7m2.1m1.8m2.1m2.5m2.5m2.2m1.9m2.0m1.7m2.4m1.6m1.6m1.7m1.6m1.6m1.6m1.7m1.3m1.8m1.9m1.8m2.3m1.7m

Operating expense total

3.1m3.4m3.5m3.5m4.0m4.4m4.1m4.2m4.9m4.8m4.1m4.6m4.4m3.7m3.5m2.5m3.0m3.1m2.7m2.3m2.4m3.1m2.9m2.7m3.0m3.0m3.2m3.2m

EBIT

(3.2m)(3.6m)(3.7m)(3.6m)(5.0m)(4.6m)(4.7m)(4.5m)(5.1m)(5.1m)(4.3m)(4.9m)(4.9m)(4.0m)(3.7m)(2.8m)(3.2m)(3.2m)(2.7m)(2.7m)(2.6m)(3.2m)(3.0m)(2.9m)(3.2m)(3.2m)(3.3m)(3.3m)

EBIT margin, %

(9022%)(7904%)(5204%)(7414%)(12731%)(10862%)(13150%)(12386%)(6726%)(14125%)(9620%)(13675%)(10428%)(17317%)(9433%)(18760%)(14664%)(3858%)(1282%)(2947%)(4589%)(9779%)(7995%)(11117%)(5254%)(7389%)(8350%)

Interest expense

11.0k49.0k2.0k55.0k

Interest income

61.0k55.0k40.0k26.0k21.0k13.0k4.0k51.0k

Net Income

(2.3m)(2.7m)(2.3m)(3.0m)(6.6m)(3.6m)(4.3m)(5.1m)(3.8m)(5.0m)(4.2m)(3.4m)(4.8m)(3.8m)(2.2m)(1.3m)(2.9m)(2.8m)(2.2m)(1.3m)(2.7m)(2.4m)(3.1m)(3.4m)(2.0m)(2.9m)(3.8m)(3.4m)

AIM ImmunoTech Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.1m4.0m3.7m2.2m3.2m1.6m1.3m1.6m4.1m2.6m1.3m2.9m1.8m1.2m1.0m1.5m4.5m776.0k1.2m503.0k4.0m3.6m4.1m2.4m959.0k9.6m27.6m33.9m

Accounts Receivable

41.0k98.0k42.0k29.0k35.0k28.0k101.0k76.0k62.0k46.0k46.0k

Prepaid Expenses

468.0k371.0k346.0k425.0k257.0k293.0k359.0k332.0k333.0k246.0k235.0k432.0k338.0k278.0k363.0k378.0k559.0k636.0k607.0k626.0k995.0k1.0m840.0k874.0k814.0k829.0k799.0k118.0k

Current Assets

33.0m34.2m33.6m30.5m36.5m38.6m32.9m29.6m21.9m20.5m17.7m17.9m17.1m14.0m9.5m10.7m9.3m5.2m4.7m3.7m5.7m5.3m4.9m5.9m3.8m12.6m29.7m35.2m

PP&E

4.8m4.7m5.1m5.3m5.3m5.1m5.0m5.1m4.9m4.8m4.7m11.8m11.7m11.5m10.9m10.1m9.8m9.3m9.0m8.8m8.4m8.1m8.0m7.6m7.5m7.3m7.0m6.8m

Total Assets

47.6m45.5m42.7m41.1m48.6m51.7m46.1m42.9m35.0m33.5m30.6m30.8m29.9m26.5m21.5m21.9m21.6m16.9m16.1m14.7m16.3m15.7m15.2m16.0m13.8m22.5m42.4m50.1m

Accounts Payable

1.1m1.6m2.5m1.8m2.3m1.7m967.0k1.7m1.2m1.5m2.4m2.3m1.6m1.5m1.4m1.4m1.0m927.0k972.0k460.0k850.0k689.0k791.0k768.0k672.0k620.0k165.0k255.0k

Short-term debt

65.0k57.0k49.0k50.0k49.0k43.0k35.0k34.0k31.0k31.0k29.0k15.0k7.0k3.0k222.0k195.0k197.0k201.0k205.0k2.3m252.0k253.0k

Current Liabilities

1.9m3.6m6.0m7.4m9.8m10.0m9.9m10.6m3.0m4.2m4.3m3.8m3.1m3.3m3.1m4.4m2.4m2.6m2.7m2.2m2.7m2.1m5.0m2.1m1.7m4.2m703.0k833.0k

Long-term debt

123.0k112.0k86.0k73.0k64.0k45.0k37.0k31.0k15.0k7.0k3.0k517.0k1.5m2.4m2.4m2.4m2.4m2.4m2.3m6.5m2.2m

Total Debt

188.0k169.0k135.0k123.0k113.0k88.0k72.0k65.0k46.0k38.0k32.0k15.0k7.0k3.0k517.0k1.5m2.7m2.6m2.6m2.6m2.6m4.6m6.7m2.5m

Total Liabilities

3.9m5.0m6.6m7.6m12.0m10.3m10.0m10.7m3.0m4.2m4.3m

Common Stock

135.0k135.0k136.0k136.0k148.0k167.0k167.0k167.0k183.0k189.0k194.0k226.0k245.0k248.0k247.0k249.0k24.0k26.0k29.0k31.0k39.0k47.0k48.0k63.0k2.0k6.0k28.0k34.0k

Preferred Stock

737.0k

Additional Paid-in Capital

264.8m264.9m265.0m265.2m274.7m288.9m289.1m289.2m296.1m298.2m299.6m308.0m312.8m313.2m313.3m313.6m315.9m316.2m316.3m316.7m321.6m322.9m323.4m323.3m329.3m340.0m366.2m381.4m

Retained Earnings

(220.9m)(223.6m)(229.0m)(232.0m)(238.6m)(247.7m)(252.0m)(257.1m)(264.2m)(269.1m)(273.3m)(281.2m)(286.1m)(289.9m)(295.2m)(296.5m)(299.3m)(303.3m)(306.0m)(306.8m)(311.5m)(313.9m)(317.0m)(321.9m)(324.0m)(326.9m)(331.9m)(335.3m)

Total Equity

43.7m40.6m36.1m33.5m36.6m41.4m36.1m32.2m32.0m29.4m26.4m27.0m26.8m23.2m18.4m17.5m16.6m12.9m10.3m10.0m10.2m9.1m6.4m3.9m6.5m13.8m35.1m47.0m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0.3 x0.3 x0.4 x0.7 x0.4 x0.2 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.2 x1.2 x1.3 x1.2 x1.3 x1.3 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.2 x1.3 x1.3 x1.3 x1.6 x1.5 x1.6 x1.7 x2.4 x4.1 x2.1 x1.6 x1.2 x1.1 x

AIM ImmunoTech Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.2m)(5.9m)(2.3m)(5.3m)(11.9m)(3.6m)(7.9m)(13.0m)(3.8m)(8.8m)(13.0m)(3.4m)(8.3m)(12.1m)(2.2m)(3.5m)(6.3m)(2.8m)(5.0m)(6.3m)(2.7m)(5.1m)(8.2m)(3.4m)(5.4m)(8.3m)(3.8m)(7.2m)

Depreciation and Amortization

198.0k322.0k149.0k296.0k469.0k179.0k350.0k648.0k332.0k608.0k914.0k251.0k537.0k829.0k300.0k576.0k854.0k261.0k504.0k739.0k216.0k444.0k658.0k222.0k415.0k610.0k381.0k407.0k

Accounts Receivable

(41.0k)(98.0k)(42.0k)(6.0k)(11.0k)(4.0k)(993.0k)1.0m1.0m(2.0k)774.0k

Inventories

(179.0k)(302.0k)(211.0k)(211.0k)(680.0k)453.0k453.0k(480.0k)(1.0m)(1.3m)

Accounts Payable

(140.0k)319.0k775.0k256.0k925.0k(358.0k)(1.0m)(197.0k)(16.0k)238.0k1.2m236.0k189.0k97.0k182.0k178.0k(202.0k)103.0k85.0k174.0k245.0k126.0k277.0k87.0k38.0k24.0k(307.0k)(217.0k)

Cash From Operating Activities

(4.8m)(7.1m)(1.7m)(5.5m)(8.2m)(5.9m)(9.6m)(13.6m)(2.9m)(6.2m)(9.9m)(4.3m)(9.2m)(12.7m)(1.0m)(2.3m)(5.3m)(3.0m)5.3m(7.2m)(2.5m)(5.2m)(8.2m)(1.5m)(4.2m)(6.8m)(3.1m)(4.5m)

Purchases of PP&E

(381.0k)(849.0k)(1.6m)(3.2m)(4.8m)(244.0k)(534.0k)(747.0k)(65.0k)(266.0k)(386.0k)(47.0k)(240.0k)(226.0k)(160.0k)(160.0k)(3.0k)(3.0k)(20.0k)(48.0k)(14.0k)(63.0k)(68.0k)(7.0k)(9.0k)

Cash From Investing Activities

4.0m7.1m1.6m1.9m(5.1m)5.2m8.8m13.1m(177.0k)(420.0k)651.0k(192.0k)(355.0k)2.1m(60.0k)1.6m2.9m486.0k1.5m1.6m1.0m993.0k1.6m(1.1m)(626.0k)(858.0k)3.5m601.0k

Short-term Borrowings

(4.3m)

Long-term Borrowings

(31.0k)(50.0k)(13.0k)(25.0k)(35.0k)(13.0k)(29.0k)(36.0k)(11.0k)(18.0k)(24.0k)(7.0k)(15.0k)(19.0k)(19.0k)(97.0k)(181.0k)(84.0k)(169.0k)(254.0k)(86.0k)(176.0k)

Dividends Paid

507.0k388.0k(135.0k)(135.0k)

Cash From Financing Activities

(31.0k)1.1m569.0k2.6m13.3m(13.0k)(29.0k)(36.0k)6.4m8.4m9.7m5.2m9.3m9.7m1.0k162.0k4.7m875.0k2.6m3.6m4.1m6.4m9.3m4.7m5.5m17.0m25.7m36.4m

Net Change in Cash

(840.0k)1.1m547.0k(933.0k)55.0k(624.0k)(906.0k)(614.0k)3.3m1.8m459.0k786.0k(314.0k)(995.0k)(1.1m)(577.0k)2.4m(1.6m)(1.2m)(1.9m)2.5m2.2m2.6m2.1m660.0k9.3m26.1m32.4m

Interest Paid

(12.0k)21.0k(9.0k)(9.0k)2.0k(2.0k)(3.0k)

AIM ImmunoTech Ratios

USDQ2, 2011

Financial Leverage

1.1 x

AIM ImmunoTech Employee Rating

2.110 votes
Culture & Values
2.2
Work/Life Balance
2.3
Senior Management
2
Salary & Benefits
1.7
Career Opportunities
1.8
Source